blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3183009

EP3183009 - CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.06.2024
Database last updated on 20.07.2024
FormerThe patent has been granted
Status updated on  07.07.2023
FormerGrant of patent is intended
Status updated on  02.03.2023
FormerExamination is in progress
Status updated on  23.04.2021
FormerRequest for examination was made
Status updated on  26.05.2017
FormerThe international publication has been made
Status updated on  08.04.2017
Formerunknown
Status updated on  24.03.2017
Most recent event   Tooltip19.07.2024Lapse of the patent in a contracting state
New state(s): CH		published on 21.08.2024 [2024/34]
Applicant(s)For all designated states
Duke University
2812 Erwin Road, Suite 306 P.O. Box 90083
Durham, North Carolina 27705 / US
[2017/29]
Former [2017/26]For all designated states
Laderx LLC
3105 Cone Manor Lane
Raleigh, North Carolina 27613 / US
Inventor(s)01 / LASCOLA, Christopher David
3414 Dover Rd.
Durham, North Carolina 27707 / US
 [2017/26]
Representative(s)Kransell & Wennborg KB
P.O. Box 27834
115 93 Stockholm / SE
[2017/26]
Application number, filing date16784310.129.09.2016
[2017/26]
WO2016US54478
Priority number, dateUS201562234986P30.09.2015         Original published format: US 201562234986 P
US201662291138P04.02.2016         Original published format: US 201662291138 P
[2017/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017059091
Date:06.04.2017
Language:EN
[2017/14]
Type: A1 Application with search report 
No.:EP3183009
Date:28.06.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 06.04.2017 takes the place of the publication of the European patent application.
[2017/26]
Type: B1 Patent specification 
No.:EP3183009
Date:09.08.2023
Language:EN
[2023/32]
Search report(s)International search report - published on:EP06.04.2017
ClassificationIPC:A61K49/10
[2017/26]
CPC:
A61K49/10 (EP,KR,US); A61K49/06 (US); A61B5/0042 (KR,US);
A61B5/0044 (KR,US); A61B5/055 (KR,US); A61K47/02 (KR,US);
A61K47/26 (KR,US); A61K9/0019 (KR,US); A61K9/08 (KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/26]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:KONTRASTMITTEL ZUR MAGNETRESONANZABBILDUNG[2017/26]
English:CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING[2017/26]
French:AGENTS DE CONSTRASTE POUR IMAGERIE PAR RÉSONNANCE MAGNÉTIQUE[2017/26]
Entry into regional phase23.03.2017National basic fee paid 
23.03.2017Designation fee(s) paid 
23.03.2017Examination fee paid 
Examination procedure23.03.2017Amendment by applicant (claims and/or description)
23.03.2017Examination requested  [2017/26]
23.03.2017Date on which the examining division has become responsible
22.04.2021Despatch of a communication from the examining division (Time limit: M04)
10.08.2021Reply to a communication from the examining division
01.10.2021Despatch of a communication from the examining division (Time limit: M04)
14.01.2022Reply to a communication from the examining division
16.03.2022Despatch of a communication from the examining division (Time limit: M04)
28.06.2022Reply to a communication from the examining division
01.09.2022Despatch of a communication from the examining division (Time limit: M04)
11.01.2023Reply to a communication from the examining division
03.03.2023Communication of intention to grant the patent
28.06.2023Fee for grant paid
28.06.2023Fee for publishing/printing paid
28.06.2023Receipt of the translation of the claim(s)
Opposition(s)13.05.2024No opposition filed within time limit [2024/29]
Fees paidRenewal fee
27.09.2018Renewal fee patent year 03
27.09.2019Renewal fee patent year 04
28.09.2020Renewal fee patent year 05
27.09.2021Renewal fee patent year 06
27.09.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT09.08.2023
CZ09.08.2023
DK09.08.2023
EE09.08.2023
ES09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
MC09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SK09.08.2023
SM09.08.2023
IE29.09.2023
LU29.09.2023
CH30.09.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
[2024/34]
Former [2024/33]AT09.08.2023
CZ09.08.2023
DK09.08.2023
EE09.08.2023
ES09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
MC09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SK09.08.2023
SM09.08.2023
IE29.09.2023
LU29.09.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/28]AT09.08.2023
CZ09.08.2023
DK09.08.2023
EE09.08.2023
ES09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
MC09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SK09.08.2023
SM09.08.2023
LU29.09.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/25]AT09.08.2023
CZ09.08.2023
DK09.08.2023
EE09.08.2023
ES09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SK09.08.2023
SM09.08.2023
LU29.09.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/23]AT09.08.2023
CZ09.08.2023
DK09.08.2023
EE09.08.2023
ES09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SK09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/22]AT09.08.2023
CZ09.08.2023
DK09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/20]AT09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RS09.08.2023
SE09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/10]AT09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RS09.08.2023
SE09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/09]AT09.08.2023
FI09.08.2023
LT09.08.2023
NL09.08.2023
SE09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
Former [2024/08]LT09.08.2023
NL09.08.2023
NO09.11.2023
GR10.11.2023
Cited inInternational search[A]WO9811921  (NYCOMED IMAGING AS [NO], et al) [A] 1-26 * page 2, 3rd full paragraph ** claims 1, 2, 8 *;
 [Y]  - V. SREEJA ET AL, "Water-dispersible ascorbic-acid-coated magnetite nanoparticles for contrast enhancement in MRI", APPLIED NANOSCIENCE, (20140722), vol. 5, no. 4, doi:10.1007/s13204-014-0335-0, ISSN 2190-5509, pages 435 - 441, XP055326046 [Y] 1-12,14-25 * whole document and in particular the abstract *

DOI:   http://dx.doi.org/10.1007/s13204-014-0335-0
 [Y]  - KOICHIRO HAYASHI ET AL, "Superparamagnetic Nanoparticle Clusters for Cancer Theranostics Combining Magnetic Resonance Imaging and Hyperthermia Treatment", THERANOSTICS, AU, (20130423), vol. 3, no. 6, doi:10.7150/thno.5860, ISSN 1838-7640, pages 366 - 376, XP055326901 [Y] 1-12,14-25 * whole document and in particular the abstract *

DOI:   http://dx.doi.org/10.7150/thno.5860
 [A]  - Anonymous, "Product information - Sodium Ascorbate Solution 112,49 mg/mL", (20110101), URL: http://www.hugogalindosalom.com/images/pdf/inserto.pdf, (20161206), XP055326279 [A] 1-26 * whole document and in particular page 1, "Description"; page 3, "Indications" and page 8 *
by applicantUS2014154185
 US2014234210
 US2014350193
    - YADAV NN; XU J; BAR-SHIR A; QIN Q; CHAN KW; GRGAC K; LI W; MCMAHON MT; VAN ZIJL PC, "Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer", MAGN RESON MED., (201212), vol. 68, no. 6, doi:doi:10.1002/mrm.24520, pages 1764 - 1773, XP055212035

DOI:   http://dx.doi.org/10.1002/mrm.24520
    - YADAV NN; XU J; BAR-SHIR A; QIN Q; CHAN KW; GRGAC K; LI W; MCMAHON MT; VAN ZIJL PC, "Natural D-glucose as a biodegradable MRI relaxation agent", MAGN RESON MED., (201409), vol. 72, no. 3, pages 823 - 828
    - BORS W; BUETTNER GR, The vitamin C radical and its reactions in Vitamin C in Health and Disease, MARCEL DEKKER, INC., (1997), pages 75 - 94
    - LACHAPELLE, M. Y.; DROUIN, G., "Inactivation dates of the human and guinea pig vitamin C genes", GENETICA, (2010), vol. 139, no. 2, doi:doi:10.1007/s10709-010-9537-x, pages 199 - 207, XP019881162

DOI:   http://dx.doi.org/10.1007/s10709-010-9537-x
    - HEDIGER MA, "New view at C", NAT. MED., (200205), vol. 8, no. 5, doi:doi:10.1038/nm0502-445, pages 445 - 446, XP002349157

DOI:   http://dx.doi.org/10.1038/nm0502-445
    - MAY JM; QU ZC; NEEL DR; LI X, "Recycling of vitamin C from its oxidized forms by human endothelial cells", BIOCHIM. BIOPHYS. ACTA, (200305), vol. 1640, no. 2-3, doi:doi:10.1016/S0167-4889(03)00043-0, pages 153 - 161, XP004422707

DOI:   http://dx.doi.org/10.1016/S0167-4889(03)00043-0
    - SAVINI I; ROSSI A; PIERRO C; AVIGLIANO L; CATANI MV, "SVCT1 and SVCT2: key proteins for vitamin C uptake", AMINO ACIDS, (200804), vol. 34, no. 3, pages 347 - 355, XP019634470
    - RUMSEY SC; KWON O; XU GW; BURANT CF; SIMPSON I; LEVINE M, "Glucose transporter isoforms GLUT 1 and GLUT3 transport dehydroascorbic acid", J. BIOL. CHEM., (199707), vol. 272, no. 30, pages 18982 - 18989
    - OREOPOULOS DG; LINDEMAN RD; VANDERJAGT DJ; TZAMALOUKAS AH; BHAGAVAN HN; GARRY PJ, "Renal excretion of ascorbic acid: effect of age and sex", J AM COLL NUTR, (199310), vol. 12, no. 5, pages 537 - 542
    - LEVINE M; CONRY-CANTILENA C; WANG Y; WELCH RW; WASHKO PW; DHARIWAL KR; PARK JB; LAZAREV A; GRAUMLICH JF; KING J, "Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance", PROC. NATL. ACAD. SCI. U.S.A., (199604), vol. 93, no. 8, pages 3704 - 3709
    - HOFFER LJ.; LEVINE M.; ASSOULINE S.; MELNYCHUK D.; PADAYATTY SJ.; ROSADIUK K.; ROUSSEAU C.; ROBITAILLE L.; MILLER WH., JR., "Phase I clinical trial of i.v. ascorbic acid in advanced malignancy", ANN ONCOL, (2008), vol. 19, pages 1969 - 1974
    - CHEN Q.; ESPEY MG.; SUN AY.; POOPUT C.; KIRK KL.; KRISHNA MC.; KHOSH DB.; DRISKO J.; LEVINE M., "Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice", PROC NATL ACAD SCI U S A, (2008), vol. 105, pages 11105 - 11109
    - CARVER, J. P.; RICHARDS, R. E. J., "General 2-Site Solution For Chemical Exchange Produced Dependence Of T2 Upon Carr-Purcell Pulse Separation", J. MAGN. RESON., (1972), vol. 6, doi:doi:10.1016/0022-2364(72)90090-X, pages 89 - 105, XP023955702

DOI:   http://dx.doi.org/10.1016/0022-2364(72)90090-X
    - HILLS, B. P.; WRIGHT, K. M.; BELTON, P. S. N.M.R., "studies of water proton relaxation in Sephadex bead suspensions", MOL. PHYS., (1989), vol. 67, pages 1309 - 1326
    - LIEPINSH E; OTTING, G, "Proton exchange rates from amino acid side chains - implications for image contrast", MAGN RESON MED., (1996), vol. 35, no. 1, pages 30 - 42, XP000580457
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.